Regenxbio Inc
General ticker "RGNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $460.9M
Regenxbio Inc does not follow the US Stock Market performance with the rate: -26.6%.
Estimated limits based on current volatility of 4.5%: low 7.32$, high 8.01$
Factors to consider:
- Current price 41.3% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [12.98$, 26.47$]
- 2024-12-30 to 2025-12-30 estimated range: [15.10$, 29.20$]
Financial Metrics affecting the RGNX estimates:
- Negative: Non-GAAP EPS, $ of -6.03 <= 0.10
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -20.43 <= 2.35
- Negative: Operating profit margin, % of -74.82 <= 1.03
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term RGNX quotes
Long-term RGNX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $470.35MM | $112.72MM | $90.24MM |
| Operating Expenses | $310.37MM | $375.60MM | $358.37MM |
| Operating Income | $159.98MM | $-262.88MM | $-268.13MM |
| Non-Operating Income | $-18.73MM | $-17.53MM | $4.48MM |
| Interest Expense | $26.28MM | $23.25MM | $6.86MM |
| R&D Expense | $181.44MM | $242.45MM | $232.27MM |
| Income(Loss) | $141.25MM | $-280.40MM | $-263.65MM |
| Taxes | $13.41MM | $-0.08MM | $-0.15MM |
| Profit(Loss) | $127.84MM | $-280.32MM | $-263.49MM |
| Stockholders Equity | $764.30MM | $516.20MM | $311.74MM |
| Inventory | $18.75MM | $13.90MM | $0.00MM |
| Assets | $1,113.90MM | $833.27MM | $573.97MM |
| Operating Cash Flow | $218.88MM | $-207.49MM | $-218.41MM |
| Capital expenditure | $84.17MM | $30.72MM | $9.96MM |
| Investing Cash Flow | $-406.64MM | $-11.93MM | $190.94MM |
| Financing Cash Flow | $195.25MM | $-28.84MM | $-34.97MM |
| Earnings Per Share* | $3.01 | $-6.50 | $-6.02 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.